Compared to the CN Aβ− group, the Alzheimer's continuum group showed abnormal AD biomarker levels (i.e., AV45 global SUVR, CSF total tau, CSF p‐tau181) and cognition (ADNI‐MEM, MMSE), and these abnormalities increased in symptomatic stages (i.e., MCI Aβ+, AD dementia). Here, MAPT is linked to Alzheimer disease.